Healthcare Industry

KKR's $4.3bn purchase of Integer Holdings, a medical device components maker, lands the same week Lantheus Holdings agrees to be acquired for an initial $6.7bn, and together they confirm that healthcare infrastructure and diagnostics, not biotech pipelines, are where big capital wants exposure right now. Integer supplies components into cardiac and neuromodulation devices for the likes of Medtronic and Abbott, giving KKR a picks-and-shovels position in a device market growing faster than pharma. Lantheus, meanwhile, makes its money on radiopharmaceutical diagnostics tied to Alzheimer's and cancer imaging, a segment insulated from the patent-cliff risk hammering traditional pharma valuations. Both deals price in double-digit premiums, and both bidders are betting stable, recurring device and diagnostics revenue outlasts patience for binary drug trial outcomes.

Cochlear plunged the most in 30 years after cutting full-year profit guidance by 15 percent, citing slower hearing implant adoption rates in key markets. The Australian medical device maker blamed delayed surgeries and cautious patient spending on elective procedures. Revenue growth slowed to 3 percent in the latest quarter, well below the 8-12 percent range Cochlear maintained for the past five years. The guidance cut suggests post-pandemic healthcare normalization is taking longer than medical device companies anticipated.